U.S. stocks shot higher on Wednesday, rebounding from six consecutive days of declines that pushed the major averages into correction territory.» Read More
Two Strategists favor U.S. stocks vs. global stocks
Health-care stocks are batting 12 for 12 in beating earnings estimates. Will the streak last?
Valuation are "very high" in the pharmaceutical sector, Roche CEO Severin Schwan told CNBC on Thursday after the company posted a rise in sales.
July 20- Bristol-Myers Squibb Co said a late-stage trial of its drug, Opdivo, was stopped early after the immunotherapy was found to be effective in patients with the most common form of kidney cancer. The drug competes with Merck& Co's Keytruda. AstraZeneca Plc, Pfizer Inc and other drugmakers are also developing PD-1 inhibitors, or similar drugs known as PD-L1...
Jim Cramer says don't give up on the banks & tech stocks yet! Sometimes there is more than one way to skin a cat.
U.S. stocks closed more than 1 percent higher, following gains overseas on news of a bailout agreement between Greece and its creditors.
Some of the names on the move ahead of the open.
U.S. stocks ended little changed as investors eyed the jobs report and were on edge ahead of Greece's Sunday referendum.
Automatic generic-drug substitution poses several big problems, says NYU Professor Melissa Schilling.
U.S. stocks closed higher, following a global rally in equities, as investors cheered signs of progress in the Greece debt negotiations.
NEW YORK, June 17- Merck& Co Inc has agreed to pay $5.9 million to resolve claims that a former unit fraudulently promoted a drug used to treat pink eye for unapproved purposes, U.S. authorities announced on Wednesday. Attorney Preet Bharara said Inspire Pharmaceuticals, which Merck acquired in 2011 and later sold, promoted its drug AzaSite to healthcare...
U.S. stocks traded lower as uncertainty over Greece weighed on sentiment and investors kept an eye on bond yields ahead of next week's FOMC meeting.
Jim Cramer discusses the huge moves that the biotech stocks have made recently—do these moves make sense for your portfolio?
June 8- Details of a large heart safety study presented on Monday appear to give Merck and Co's diabetes drug Januvia a clean bill of health, possibly setting the stage for a return to sales growth for the drugmaker's biggest product. Januvia, an oral medication known chemically as sitagliptin that helps lower blood sugar levels, had sales of about $4 billion in...
June 4- A bipartisan group of U.S. lawmakers introduced legislation on Thursday to boost protections for pregnant workers in response to a recent U.S. Supreme Court ruling that revived discrimination claims by a former United Parcel Service Inc driver. The group of lawmakers backing the bill includes Senator Kelly Ayotte, a Republican from New Hampshire, but...
CNBC Pro found some of the stocks that are trading at a discount and have solid growth expectations for the future.
CHICAGO, June 2- Drugmakers including Bristol-Myers Squibb Co and Merck& Co are testing which patients will most benefit from new cancer treatments based on a protein found in their tumors, but that guide, known as a biomarker, may be too unreliable, researchers and health experts said. Competitors Roche Holding, AstraZeneca and Pfizer also have similar drugs in...
The stock-moving news flow started early out of the American Society of Clinical Oncology meeting in Chicago.
Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival in a trial of patients with the most common form of lung cancer, but it did not work in patients who tested negative for a specific protein in their tumors, leading to a nearly 7 percent sell-off in the company's shares on Friday. The Bristol drug was approved by U.S. regulators in December to...
U.S. stocks closed lower on the last trading day of the month, as investors digested data and remained cautious on continued concerns about Greece.